EDIT PE Ratio & Valuation,Is EDIT Overvalued

EDIT Relative Valuation

EDIT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, EDIT is overvalued; if below, it's undervalued.

Historical Valuation

Editas Medicine Inc (EDIT) is now in the Overvalued zone, suggesting that its current forward PS ratio of 13.59 is considered Overvalued compared with the five-year average of -5.46. The fair price of Editas Medicine Inc (EDIT) is between 1.12 to 2.51 according to relative valuation methord. Compared to the current price of 2.53 USD , Editas Medicine Inc is Overvalued By 0.97%.

Relative Value

Fair Zone

1.12-2.51

Current Price：2.53

0.97%

Overvalued

-2.20

-0.89

EV/EBITDA

Editas Medicine Inc. (EDIT) has a current EV/EBITDA of -0.89. The 5-year average EV/EBITDA is -3.10. The thresholds are as follows: Strongly Undervalued below -12.70, Undervalued between -12.70 and -7.90, Fairly Valued between 1.70 and -7.90, Overvalued between 1.70 and 6.51, and Strongly Overvalued above 6.51. The current Forward EV/EBITDA of -0.89 falls within the Historic Trend Line -Fairly Valued range.

-0.85

EV/EBIT

Editas Medicine Inc. (EDIT) has a current EV/EBIT of -0.85. The 5-year average EV/EBIT is -3.01. The thresholds are as follows: Strongly Undervalued below -12.36, Undervalued between -12.36 and -7.69, Fairly Valued between 1.66 and -7.69, Overvalued between 1.66 and 6.33, and Strongly Overvalued above 6.33. The current Forward EV/EBIT of -0.85 falls within the Historic Trend Line -Fairly Valued range.

13.59

Editas Medicine Inc. (EDIT) has a current PS of 13.59. The 5-year average PS is 59.61. The thresholds are as follows: Strongly Undervalued below -72.49, Undervalued between -72.49 and -6.44, Fairly Valued between 125.66 and -6.44, Overvalued between 125.66 and 191.71, and Strongly Overvalued above 191.71. The current Forward PS of 13.59 falls within the Historic Trend Line -Fairly Valued range.

-2.48

P/OCF

Editas Medicine Inc. (EDIT) has a current P/OCF of -2.48. The 5-year average P/OCF is -5.94. The thresholds are as follows: Strongly Undervalued below -18.02, Undervalued between -18.02 and -11.98, Fairly Valued between 0.10 and -11.98, Overvalued between 0.10 and 6.14, and Strongly Overvalued above 6.14. The current Forward P/OCF of -2.48 falls within the Historic Trend Line -Fairly Valued range.

-2.41

P/FCF

Editas Medicine Inc. (EDIT) has a current P/FCF of -2.41. The 5-year average P/FCF is -6.17. The thresholds are as follows: Strongly Undervalued below -19.30, Undervalued between -19.30 and -12.74, Fairly Valued between 0.40 and -12.74, Overvalued between 0.40 and 6.97, and Strongly Overvalued above 6.97. The current Forward P/FCF of -2.41 falls within the Historic Trend Line -Fairly Valued range.

Editas Medicine Inc (EDIT) has a current Price-to-Book (P/B) ratio of 17.57. Compared to its 3-year average P/B ratio of 3.84 , the current P/B ratio is approximately 357.57% higher. Relative to its 5-year average P/B ratio of 3.94, the current P/B ratio is about 345.86% higher. Editas Medicine Inc (EDIT) has a Forward Free Cash Flow (FCF) yield of approximately -73.17%. Compared to its 3-year average FCF yield of -65.20%, the current FCF yield is approximately 12.21% lower. Relative to its 5-year average FCF yield of -43.63% , the current FCF yield is about 67.71% lower.

17.57

P/B

Median3y

3.84

Median5y

3.94

-73.17

FCF Yield

Median3y

-65.20

Median5y

-43.63

Competitors Valuation Multiple

The average P/S ratio for EDIT's competitors is 8.43, providing a benchmark for relative valuation. Editas Medicine Inc Corp (EDIT) exhibits a P/S ratio of 13.59, which is 61.23% above the industry average. Given its robust revenue growth of 12265.57%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of EDIT increased by 99.21% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 61.00K to 7.54M.

The secondary factor is the Margin Expansion, contributed -99.67%to the performance.

Overall, the performance of EDIT in the past 1 year is driven by Revenue Growth. Which is more sustainable.

12265.57%

61.00K → 7.54M

Revenue Growth

-99.67%

-101.87K → -332.98

Margin Expansion

-12066.69%

0.01 → -1.08

P/E Change

99.21%

1.27 → 2.53

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Editas Medicine Inc (EDIT) currently overvalued or undervalued?

What is Editas Medicine Inc (EDIT) fair value?

EDIT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Editas Medicine Inc (EDIT) is between 1.12 to 2.51 according to relative valuation methord.

How does EDIT's valuation metrics compare to the industry average?

What is the current P/B ratio for Editas Medicine Inc (EDIT) as of Dec 15 2025?

As of Dec 15 2025, Editas Medicine Inc (EDIT) has a P/B ratio of 17.57. This indicates that the market values EDIT at 17.57 times its book value.

What is the current FCF Yield for Editas Medicine Inc (EDIT) as of Dec 15 2025?

As of Dec 15 2025, Editas Medicine Inc (EDIT) has a FCF Yield of -73.17%. This means that for every dollar of Editas Medicine Inc’s market capitalization, the company generates -73.17 cents in free cash flow.

What is the current Forward P/E ratio for Editas Medicine Inc (EDIT) as of Dec 15 2025?

As of Dec 15 2025, Editas Medicine Inc (EDIT) has a Forward P/E ratio of -2.20. This means the market is willing to pay $-2.20 for every dollar of Editas Medicine Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Editas Medicine Inc (EDIT) as of Dec 15 2025?

As of Dec 15 2025, Editas Medicine Inc (EDIT) has a Forward P/S ratio of 13.59. This means the market is valuing EDIT at $13.59 for every dollar of expected revenue over the next 12 months.

EDIT Valuation